微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2012, Vol. 4 ›› Issue (3): 251-255.doi: 10.3969/j.issn.1674-5671.2012.03.11

• 临床研究 • 上一篇    下一篇

ERCC1、RRM1基因表达与非小细胞肺癌患者预后的相关性

  

  1. 广西医科大学附属肿瘤医院胸瘤外科；广西医科大学研究生学院
  • 出版日期:2012-09-25 发布日期:2012-10-15
  • 通讯作者: 刘德森 E-mail:desenliu57@hotmail.com
  • 基金资助:

    广西壮族自治区卫生厅重点科研课题（重 NO 200872）

Correlation of ERCC1 and RRM1 expression and survival prognosis in non-small cell lung cancer patients

  • Online:2012-09-25 Published:2012-10-15

PDF (PC)

450

赞

被引次数

4

摘要： 目的 探讨ERCC1、RRM1基因蛋白表达对Ⅰ～Ⅲa期非小细胞肺癌患者预后的影响。方法 采用免疫组化法检测Ⅰ～Ⅲa期非小细胞肺癌患者ERCC1、RRM1蛋白表达情况；采用生存分析曲线分析其对生存预后的影响。结果 ERCC1、RRM1蛋白表达与患者性别、年龄、病理类型和TNM分期等差异均无统计学意义（P >0.05）。在TNM分期中，Ⅰa期ERCC1、RRM1阳性表达组生存预后较好，提示两种基因蛋白的阳性表达在Ⅰa期患者中是一种保护因素。在Ⅰb～Ⅲa期患者中ERCC1表达阴性组可以从含铂化疗方案中获益，可获得生存优势；RRM1表达阴性组对化疗药物吉西他滨敏感，可获得较长的生存优势。在Ⅰ～Ⅲa期患者中ERCC1与RRM1的表达呈正相关，差异有统计学意义（P <0.05）。结论 检测Ⅰ～Ⅲa期非小细胞肺癌ERCC1及RRM1蛋白表达可以预测患者的治疗疗效及预后，使患者从个体化治疗中获益。

关键词: 肺肿瘤, ERCC1, RRM1, 个体化治疗, 预后

Abstract: Objective To explore the effects of excision repair cross-complementing 1（ERCC1） and ribonucleotide reductase subunit （RRM1） protein expression on survival prognosis of stage I-IIIa non-small cell lung cancer（NSCLC） patients. Methods ERCC1 and RRM1 protein expression was detected in stage I-IIIa NSCLC patients using immunohistochemistry.The survival prognosis of the pa-tients was analyzed by survival analysis. Results Neither ERCC1 nor RRM1 expression was associated with gender，age，histological type，or TNM stage.The survival prognosis of ERCC1-and RRM1-positive patients in stage Ia was better than that of ERCC1-and RRM1-positive patients in other stages.ERCC1-negative patients in stage Ib-IIIa may benefit from platinum-containing chemotherapy，which may provide a survival advantage.RRM1-negative patients were sensitive to gemcitabine， which provided a survival advantage. ERCC1 expression positively correlated with RRM1 expression（P<0.05） in stage I-IIIa NSCLC patients. Conclusion Chemotherapeutic effect and prognosis of patients with stage I-IIIa NSCLC can be predicted by detecting ERCC1 and RRM1 expression，which may allow for individualized treatment plans.

Key words: Lung neeplasms, ERCC1, RRM1, Individualized chemotherapy, Prognosis